Answers are grounded in this paper and cite their sources.
Explores screening techniques to detect liver fibrosis in patients with metabolic dysfunction, suggesting improved outcomes.
What screening approach could improve early detection of 'at-risk' metabolic dysfunction-associated steatohepatitis in my patients? Q:A 54-year-old woman with type 2 diabetes mellitus (hemoglobin A1c 8.1%), body mass index 34 kg/m2, and hypertension presents for routine follow-up of her cardiometabolic diseases.Should she be screened for advanced liver fi brosis due to metabolic dysfunction-associated steatohepatitis (MASH), and what is the recommended approach to risk stratifi cation?'AT-RISK' MASH SCREENING
No takes yet. Share an insight, caveat, or question.
Naseem et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: